Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate on December 17, 2025 * * Vivek Ramaswamy * * 6-amino-1-hydroxyhexane-1,1-diphosphonate Ambros Therapeutics Analgesics, Non-Narcotic Chronic pain Complex Regional Pain Syndromes CRPS-1 Diphosphonates Series A +
FDA Approves Tonix's Tonmya: First New Fibromyalgia Drug in Over 15 Years on August 18, 2025 Analgesics, Non-Narcotic Approved Chronic pain Clinical Trials cyclobenzaprine Fibromyalgia Hairy Cell Leukemia Phase 3 sublingual tablets Tonix Tonmya United States Food and Drug Administration +